HEALTHDYNE TECHNOLOGIES INC
DFAN14A, 1997-07-28
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Previous: HEALTHDYNE TECHNOLOGIES INC, SC 14D9/A, 1997-07-28
Next: ALDILA INC, S-8, 1997-07-28



<PAGE>   1

                                  SCHEDULE 14A
                                 (RULE 14A-101)
 
                    INFORMATION REQUIRED IN PROXY STATEMENT
 
                            SCHEDULE 14A INFORMATION
          PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES
                    EXCHANGE ACT OF 1934 (AMENDMENT NO.   )
 
Filed by the Registrant [X]
 
Filed by a Party other than the Registrant [ ]
 
Check the appropriate box:
 
<TABLE>
<S>                                             <C>
[ ]  Preliminary Proxy Statement                [ ]  Confidential, for Use of the Commission
                                                     Only (as permitted by Rule 14a-6(e)(2))
[ ]  Definitive Proxy Statement
[X]  Definitive Additional Materials
[ ]  Soliciting Material Pursuant to Rule 14a-11(c) or Rule 14a-12
</TABLE>

                        HEALTHDYNE TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
                (Name of Registrant as Specified In Its Charter)


- --------------------------------------------------------------------------------
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
 
Payment of Filing Fee (Check the appropriate box):
 
[X]  No fee required.
 
[ ]  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
 
     (1)  Title of each class of securities to which transaction applies:
 
     (2)  Aggregate number of securities to which transaction applies:
 
     (3)  Per unit price or other underlying value of transaction computed
          pursuant to Exchange Act Rule 0-11 (set forth the amount on which the
          filing fee is calculated and state how it was determined):
 
     (4)  Proposed maximum aggregate value of transaction:
 
     (5)  Total fee paid:
 
[ ]  Fee paid previously with preliminary materials:
 
[ ]  Check box if any part of the fee is offset as provided by Exchange Act Rule
     0-11(a)(2) and identify the filing for which the offsetting fee was paid
     previously. Identify the previous filing by registration statement number,
     or the Form or Schedule and the date of its filing.
 
     (1)  Amount Previously Paid:
 
     (2)  Form, Schedule or Registration Statement No.:
 
     (3)  Filing Party:
 
     (4)  Date Filed:
<PAGE>   2

   
HEALTHDYNE TECHNOLOGIES                         M. Wayne Boylston
ANNOUNCES FAVORABLE COURT                       July 28, 1997
DECISION                                        (770) 499-1212




FOR IMMEDIATE RELEASE

     Marietta, Georgia, July 28, 1997 - Healthdyne Technologies, Inc.
(NASDAQ:HDTC) announced today that the Federal District Court in Atlanta upheld
Healthdyne Technologies' position to present Invacare's by-law amendment
relating to is Shareholder Rights Plan on a contingent basis at the upcoming
Annual Meeting.
     As was proposed by Healthdyne Technologies, the Court ordered that the
votes on Invacare's invalid by-law not be counted at the Annual Meeting, but
that the proxy cards and ballots be retained by the independent inspectors of
election so that the votes could be tabulated in the event the Court's prior
order invalidating the by-law is reversed on appeal.
     "We are very pleased with the Court's ruling vindicating our position that
Invacare's invalid by-law proposal be presented on a contingent basis at the
Annual Meeting," said Parker H. Petit, Chairman of the Board of Healthdyne
Technologies.
     Healthdyne Technologies designs, manufactures and markets technologically
advanced medical devices for use in the home, as well as other specialized
clinical settings.  The Company's products include diagnostic and therapeutic
devices for the evaluation and treatment of sleep disorders, non-invasive
ventilators, oxygen concentrators and medication nebulizers for the treatment
of respiratory disorders, monitors for infants at risk for SIDS, and products
for asthma management.
    



© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission